Guggenheim Maintains Buy on First Tracks, Raises Price Target to $110
First Tracks Biotherapeutics Inc TRAX
$51.43
▲ +3.48%
(+$1.73)
🎯 52W High
⬆️ Above Yest. High
🔥 High Short Interest
Open
$49.25
Prev Close
$49.70
Day Range
$48.64 – $54.79
52W Range
$14.72 – $50.41
Market Cap
$2.01B
Beta
0.66
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-04-06 |
| Shares Out. | 42,020,000 |
| Website | firsttracksbio.com ↗ |
| Phone | 12123733000 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$31.4M |
| Free Cash Flow | -$112.3M |
| Total Assets | $170.5M |
| Total Liabilities | $19.4M |
| Equity | $151.0M |
About First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
First Tracks Biotherapeutics Inc is a publicly traded company under the ticker symbol TRAX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-11-01)